Loading the session
Loading the session
Loading instrument
$110.00
−3.42%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:07 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +14.0% (SPY −1.6%, XLV +13.5%). 3 months: −24.1% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BLLN, SPY and XLV · as of 4 Nov 2026
2.9M shares were sold short at the 15 Oct 2026 settlement; covering them would take 5.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $113.89 was 8.8% above its 50-day average ($104.67) and 17.7% above its 200-day average ($96.76). It has closed above the 200-day for 16 sessions, since 14 Oct 2026.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
August 6, 2026
−38.89%February 23, 2026
−15.59%January 12, 2026
+15.37%